What is a stock summary page? Click here for an overview.
Business Description
Equillium Inc
NAICS : 325412
SIC : 2834
ISIN : US29446K1060
Description
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 58.79 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -7.89 | |||||
| Beneish M-Score | -1.22 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 45.4 | |||||
| 3-Year EPS without NRI Growth Rate | 44.7 | |||||
| 3-Year FCF Growth Rate | 21.4 | |||||
| 3-Year Book Growth Rate | -38.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -47.31 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.39 | |||||
| 9-Day RSI | 34.51 | |||||
| 14-Day RSI | 35.43 | |||||
| 3-1 Month Momentum % | -53.45 | |||||
| 6-1 Month Momentum % | -38.36 | |||||
| 12-1 Month Momentum % | -71.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.93 | |||||
| Quick Ratio | 3.93 | |||||
| Cash Ratio | 3.55 | |||||
| Days Sales Outstanding | 40.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.5 | |||||
| Shareholder Yield % | 17.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -20.12 | |||||
| Net Margin % | -19.63 | |||||
| EBITDA Margin % | -18.42 | |||||
| FCF Margin % | -46.5 | |||||
| ROE % | -37.23 | |||||
| ROA % | -20.47 | |||||
| ROIC % | -94.12 | |||||
| 3-Year ROIIC % | -965.85 | |||||
| ROC (Joel Greenblatt) % | -860.24 | |||||
| ROCE % | -35.13 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 0.61 | |||||
| PS Ratio | 0.33 | |||||
| PB Ratio | 0.7 | |||||
| Price-to-Tangible-Book | 0.69 | |||||
| EV-to-EBIT | 1.11 | |||||
| EV-to-EBITDA | 1.13 | |||||
| EV-to-Revenue | -0.21 | |||||
| EV-to-Forward-Revenue | 0.08 | |||||
| EV-to-FCF | 0.45 | |||||
| Price-to-Net-Current-Asset-Value | 0.72 | |||||
| Price-to-Net-Cash | 0.83 | |||||
| Earnings Yield (Greenblatt) % | 90.09 | |||||
| FCF Yield % | -143.08 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EQ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Equillium Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 41.095 | ||
| EPS (TTM) ($) | -0.23 | ||
| Beta | 2.54 | ||
| 3-Year Sharpe Ratio | 0.02 | ||
| 3-Year Sortino Ratio | 0.05 | ||
| Volatility % | 93.86 | ||
| 14-Day RSI | 35.43 | ||
| 14-Day ATR ($) | 0.047017 | ||
| 20-Day SMA ($) | 0.415629 | ||
| 12-1 Month Momentum % | -71.6 | ||
| 52-Week Range ($) | 0.3442 - 1.61 | ||
| Shares Outstanding (Mil) | 35.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Equillium Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Equillium Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Equillium Inc Frequently Asked Questions
What is Equillium Inc(EQ)'s stock price today?
The current price of EQ is $0.37. The 52 week high of EQ is $1.61 and 52 week low is $0.34.
When is next earnings date of Equillium Inc(EQ)?
The next earnings date of Equillium Inc(EQ) is 2025-08-08 Est..
Does Equillium Inc(EQ) pay dividends? If so, how much?
Equillium Inc(EQ) does not pay dividend.
Guru Commentaries on NAS:EQ
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers